Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004058 · ClinicalTrials.gov registry record · Phase 1
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
A Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00004058: Clinical Trial Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00004058 is a Phase 1 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004058, a Phase 1 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorder that has not responded to previous treatment.
Interventions
- DRUG tetradecanoylphorbol acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Why NCT00004058 stopped before completion
NCT00004058 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which tetradecanoylphorbol acetate is the first listed.
NCT00004058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004058 about?
NCT00004058 is a clinical study titled "12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 12-O-tetradecanoylphorbol-13-acetate in treating patients with hematologic cancer or bone marrow disorde...
What is the current status of trial NCT00004058?
This trial is currently terminated. It is a Phase 1 study. The study started on 1998-12. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00004058?
The interventions under investigation include: tetradecanoylphorbol acetate (DRUG).
Who is sponsoring clinical trial NCT00004058?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia